Web Exclusives

In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including IGHV gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›

Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors. Read More ›

Molecular/genetic characterization has taken on greater importance in the classification of adult gliomas and in diagnostic and treatment decision-making. “These tumors are now grouped and predicated more on molecular features rather than histopathologic criteria,” said L. Burt Nabors, MD, in a presentation during the 2023 National Comprehensive Cancer Network Annual Conference. Read More ›

A recent study demonstrates liquid biopsy has high concordance to tissue biopsy in non–small-cell lung cancer, making it an acceptable first-line testing option. Read More ›

A small study of patients with non–small-cell lung cancer with brain metastasis showed sotorasib had promising efficacy on brain lesions. Read More ›

A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes. Read More ›

A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab. Read More ›

Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist. Read More ›

A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results. Read More ›

Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer. Read More ›